Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE SHARES OF THE COMPANY IN STOCK LIST OF HONG KONG STOCK CONNECT

The board of directors (the "**Board**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**" or "**Xuanzhu Biopharm**", together with its subsidiaries, the "**Group**") is pleased to announce that, according to the Notice of Adjustment of the Eligible Stocks in Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect (《關於滬港通下港股通標的調整的通知》) and the Announcement on Adjustment of the List of the Eligible Stocks in Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect (《關於深港通下的港股通標的證券名單調整的公告》) issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange respectively on 6 March 2026, the Company was included in list of the eligible stocks in Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, with effect from 9 March 2026.

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are channels for share trading and investment between investors in the capital markets of Hong Kong and mainland China. The Board believes that the inclusion of the Company in the list of eligible stocks under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect will help to expand the Company's shareholder base and enhance the liquidity of the Company's shares.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is an innovative pharmaceutical company rooted in China with a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development ("**R&D**"), production and commercialization of class 1 drugs with core proprietary intellectual property rights. The Company has a first-class R&D team that all core personnel have years of experience in new drug R&D. The Company has two R&D platforms: small molecule chemistry and large molecule biopharmaceuticals. The dual engines drive the Company's innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the Company is committed to developing into a firstclass innovative pharmaceutical company with independent R&D, production, and sales capabilities.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, 8 March, 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.